Browse studies

Find your next paid study

1 recruiting study matching your filters

Olomorasib Plus Pembrolizumab as First-Line Treatment for KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

This clinical trial evaluates the combination of olomorasib and pembrolizumab as a first-line treatment for patients with advanced or metastatic non-small cell…

Lung CancerLung Cancer (NSCLC)Locally Advanced NSCLC+1 more

Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT07639242